share_log

UBS Downgrades Royalty Pharma to Neutral, Announces $28 Price Target

UBS Downgrades Royalty Pharma to Neutral, Announces $28 Price Target

瑞银将Royalty Pharma降级为中立,宣布28美元的目标价位。
Benzinga ·  06/03 11:50

UBS analyst Ashwani Verma downgrades Royalty Pharma (NASDAQ:RPRX) from Buy to Neutral and announces $28 price target.

瑞银分析师Ashwani Verma将Royalty Pharma (NASDAQ:RPRX)的评级从买入下调至中立,并宣布目标价为28美元。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发